Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

By sjmartinez • February 24, 2023

Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. PMID: 36816342; PMCID: PMC9932343.

Tags: Dermatology, Olive View DoM, Publications

Ethical considerations regarding environmental impact of generative artificial intelligence (AI) in dermatology

Ebriani J, Yan MJ, Lester J, Farshchian M, Wongvibulsin S. Ethical considerations regarding environmental impact of generative artificial intelligence (AI) in dermatology. J Am Acad[...]

Autoimmune Bullous Diseases: Therapeutic Update

Kasperkiewicz M, van Beek N, Schmidt E. Autoimmune Bullous Diseases: Therapeutic Update. Drugs. 2026 Feb 23. doi: 10.1007/s40265-026-02292-3. Epub ahead of print. PMID: 41729378.

Systemic Corticosteroid Exposure in Patients with Atopic Dermatitis: A US Population-Based Study

Bunick CG, Vleugels RA, Lebwohl M, Armstrong AW, Grada A, Yue EX, Saranadasa M, Wegrzyn L, D'Andrea E. Systemic Corticosteroid Exposure in Patients with Atopic[...]